The investment is expected to expand Novo Nordisk’s production capacity from active pharmaceutical ingredients (API) to assembly and packaging
Part of Novo Nordisk’s overall project in Kalundborg. (Credit: Novo Nordisk A/S.)
Novo Nordisk has unveiled its plans to invest more than DKK17bn ($2.5bn) to build three new manufacturing facilities and expand the existing facility at its Kalundborg production site in Denmark.
The investment is expected to expand Novo Nordisk’s production capacity from active pharmaceutical ingredients (API) to assembly and packaging.
The expansion of the Kalundborg site would facilitate the production of current and future oral and injectable products, said the company.
Novo Nordisk product supply, quality & IT EVP Henrik Wulff said: “This major investment in our manufacturing facilities in Kalundborg is an important step in building and ensuring future capacity for production of our current and future oral and injectable product portfolio.
“Kalundborg is currently the cornerstone in our production of API and the expansion of the manufacturing capacity is important to meeting the future demands of patients.
“The investment announced today emphasises our continued commitment to Denmark and Kalundborg being at the heart of our global manufacturing setup.”
Novo Nordisk said that the new facilities will be automated and feature advanced production technologies. The projects are expected to be completed in 2027.
The expansion project is anticipated to create about 400 new jobs and more than 2,500 external jobs during the construction phase.
Established in 1923, Novo Nordisk is a global healthcare company focused on diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders.
The company has initially established production facilities in Kalundborg in 1969, which currently cover an area of 1.2 million m² and employ about 3,200 workers.
At the Kalundborg site, it manufactures therapeutic products for obesity and diabetes, along with various other biopharmaceutical products.
Novo Nordisk claimed that it has invested more than DKK18bn ($2.7bn) in the manufacturing facilities at the Kalundborg site.
In February last year, the company has announced DKK 800m ($117m) investment to upgrade and expand its facilities at Kalundborg production site, Denmark.